Abstract:Vaccines are one of the most effective strategies to prevent pathogen-induced illness in humans. The earliest vaccines were based on live inoculations with low doses of live or related pathogens, which carried a relatively high risk of developing the disease they were meant to prevent. The introduction of attenuated and killed pathogens as vaccines dramatically reduced these risks; however, attenuated live vaccines still carry a risk of reversion to a pathogenic strain capable of causing disease. This risk is completely eliminated with recombinant protein or subunit vaccines, which are atoxic and non-infectious. However, these vaccines require adjuvants and often significant optimization to induce robust T-cell responses and long-lasting immune memory. Some pathogens produce protein toxins that cause or contribute to disease. To protect against the effects of such toxins, chemically inactivated toxoid vaccines have been found to be effective. Toxoid vaccines are successfully used today at a global scale to protect against tetanus and diphtheria. Recent developments for toxoid vaccines are investigating the possibilities of utilizing recombinant protein toxins mutated to eliminate biologic activity instead of chemically inactivated toxins. Finally, one of the most contemporary approaches toward vaccine design utilizes messenger RNA (mRNA) as a vaccine candidate. This approach was used globally to protect against coronavirus disease during the COVID-19 pandemic that began in 2019, due to its advantages of quick production and scale-up, and effectiveness in eliciting a neutralizing antibody response. Nonetheless, mRNA vaccines require specialized storage and transport conditions, posing challenges for low- and middle-income countries. Among multiple available technologies for vaccine design and formulation, which technology is most appropriate? This review focuses on the considerable developments that have been made in utilizing diverse vaccine technologies with a focus on vaccines targeting bacterial toxins. We describe how advancements in vaccine technology, combined with a deeper understanding of pathogen-host interactions, offer exciting and promising avenues for the development of new and improved vaccines.

Prospects for the use of viral proteins for the construction of chimeric toxins

Virus-Derived Peptides for Clinical Applications

Virus-derived Materials: Bury the Hatchet with Old Foes.

Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications

An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodies

Chemical Modification Strategies of Viral Vectors for Gene Therapy

Enhanced delivery of protein therapeutics with a diphtheria toxin-like platform that evades pre-existing neutralizing immunity

Molecular Engineering of Virus Tropism

In Situ Capture of Bacterial Toxins for Antivirulence Vaccination

Recombinant Derivatives of Clostridial Neurotoxins as Delivery Vehicles for Proteins and Small Organic Molecules

Virus-like particles as powerful vaccination strategy against human viruses

Antiviral PROTACs: Opportunity borne with challenge

Toxins and Derivatives in Molecular Pharmaceutics: Drug Delivery and Targeted Therapy.

A potential delivery system based on cholera toxin: A macromolecule carrier with multiple activities

Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines

From virus to immune system: Harnessing membrane‐derived vesicles to fight COVID‐19 by interacting with biological molecules

Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines

Viruses as biomaterials

A chimeric viral platform for directed evolution in mammalian cells

Anti-virus reagents targeting the capsid protein assembly

Artificial viruses: A nanotechnology based approach